Form 4: Akero Therapeutics COO Jonathan Young Sells Shares Under 10b5-1 Trading Plan

Akero Therapeutics' Chief Operating Officer, Jonathan Young, sold shares of common stock under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Jonathan Young, the Chief Operating Officer of Akero Therapeutics, sold shares of the company's common stock on February 3, 2025.
• The sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on June 25, 2024.
• A total of 10,000 shares were sold in two transactions at weighted-average prices of $53.565 and $54.057.
• Following the reported transactions, Young directly owns 251,147 shares of Akero Therapeutics.
• Young also disclaims beneficial ownership of 60,000 shares held in irrevocable trusts for the benefit of his children.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the document simply reports the sale of shares under a pre-existing trading plan, which is a common and legal practice.

Industry Context

Sales by company insiders are a common occurrence and are often pre-planned through Rule 10b5-1 trading plans to avoid accusations of trading on inside information. The market typically views these sales in the context of the overall insider holdings and the reasons behind the sale.

Stakeholder Impact

• The sale of shares by a company executive could be perceived negatively by some shareholders, potentially leading to a slight decrease in investor confidence.

Key Dates

Keywords

Akero Therapeutics, Jonathan Young, Form 4, Share Sale, Rule 10b5-1, AKRO, COO, Insider Trading